1,547 Shares in Amgen Inc. $AMGN Bought by Tempo Wealth LLC

Tempo Wealth LLC acquired a new position in Amgen Inc. (NASDAQ:AMGN) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,547 shares of the medical research company’s stock, valued at approximately $506,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of AMGN. Brighton Jones LLC lifted its stake in shares of Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after purchasing an additional 5,226 shares during the period. Sivia Capital Partners LLC grew its position in Amgen by 10.6% during the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after buying an additional 114 shares during the period. Schnieders Capital Management LLC. grew its position in Amgen by 29.3% during the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after buying an additional 5,853 shares during the period. Main Street Financial Solutions LLC increased its holdings in Amgen by 11.3% in the second quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company’s stock valued at $1,141,000 after buying an additional 416 shares in the last quarter. Finally, Ieq Capital LLC increased its holdings in Amgen by 5.1% in the second quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company’s stock valued at $15,120,000 after buying an additional 2,611 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Down 1.2%

Shares of NASDAQ:AMGN opened at $337.60 on Friday. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The company has a market capitalization of $182.21 billion, a P/E ratio of 23.49, a P/E/G ratio of 3.43 and a beta of 0.42. Amgen Inc. has a 52-week low of $267.83 and a 52-week high of $391.29. The stock’s fifty day simple moving average is $340.96 and its 200-day simple moving average is $345.81.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. During the same quarter last year, the business posted $4.90 EPS. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities research analysts forecast that Amgen Inc. will post 22.38 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on AMGN. Erste Group Bank reissued a “hold” rating on shares of Amgen in a research note on Tuesday, May 5th. Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a report on Sunday, June 14th. Daiwa Securities Group decreased their target price on Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 13th. Leerink Partners reissued a “market perform” rating and issued a $355.00 target price on shares of Amgen in a report on Thursday, March 5th. Finally, The Goldman Sachs Group set a $389.00 price target on Amgen in a research report on Friday, June 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Amgen presently has a consensus rating of “Hold” and a consensus price target of $354.42.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.85% of the stock is currently owned by company insiders.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.